Articles related to CAR-T THERAPY

The rapid exhaustion of T cells upon encountering a tumor, as revealed in a recent study, challenges existing theories and may have profound implications for cancer immunotherapies. Explore the findings to understand how this discovery could influence the future of personalized treatment.

The recent approval of epcoritamab for R/R DLBCL introduces a new pathway in treatment, offering substantial response rates and the potential for broader implementation beyond academic centers. Explore the detailed insights into the function, efficacy, and prospective implications of this novel therapy.

Researchers at Roswell Park Comprehensive Cancer Center have unveiled a novel approach using bispecific T-cell engagers (BiTEs) to enhance immune responses against ovarian cancer. This promising pathway may lead to improved therapeutic options for patients unresponsive to conventional immunotherapies.

The phase 3 study evaluating cilta-cel, a BCMA–directed CAR T-cell therapy, in patients with lenalidomide-refractory multiple myeloma indicates promising results in progression-free survival and overall response rates.

Join this crucial journey to broaden your comprehension of CAR T-cell therapy, CRS and ICANS management, and learn how to utilize this knowledge for better patient outcomes in the battle against relapsed/refractory multiple myeloma.

Discover how a groundbreaking trial using a new CRISPR gene-editing technique has successfully treated a patient with T-cell leukemia, a form of the disease resistant to conventional treatments. Learn how this innovative approach could revolutionize the treatment of various diseases affecting the blood, bone marrow, and immune systems.